Back To Search Instructions
Protocols
39 protocol(s) meet the specified criteria
Age Group: A
Disease Site: Prostate
Protocol No.TitleStatus
12557A Randomized Phase 2 Trial of Immediate versus Delayed Anti-CTLA4 Blockade Following Sipuleucel-T Treatment for Prostate Cancer ImmunotherapyOpen
12985The Effect of Tyrosine Kinase Inhibitors on Male Reproductive Health and Spermatozoa Function: A Prospective Observational Study of Men Receiving TKI for Treatment of Malignant TumorsOpen
13553Prostate Cancer Decision Making for Low-Income African American MenOpen
155510A Clinical Trial of High-Intensity Aerobic and Resistance Exercise for Metastatic Prostate CancerOpen
155513A Randomized Controlled Clinical Trial of a Smartphone-Based App to Improve Urinary and Sexual Function Outcomes after Robot-Assisted Laparoscopic Radical Prostatectomy SurgeryOpen
155518Precision Oncology and Molecular Targeting in Advanced Prostate Cancer: Identifying Predictive Markers of Response (The "PROMOTE" Study)Open
164520Sharing Clinical and Genomic Data for Cancer ResearchOpen
165511Targeting Adaptive Pathways in Abiraterone and Enzalutamide Refractory Intermediate Atypical CarcinomaOpen
165513A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate CancerOpen
165518A Phase 1b Study of Enzalutamide plus CC-115 in Men with Castration-Resistant Prostate Cancer (CRPC) Open
16557Phase 2 open label study of pembrolizumab in patients with metastatic castration resistant prostate cancer (mCRPC) with or without DNA damage repair defects Open
16702A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable CancersOpen
169524A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine CarcinomasOpen
16954Phase 1/2 Study of CORT125134 in Combination with Nab-paclitaxel in Patients with Solid TumorsOpen
175513A Randomized Clinical Trial of Lifestyle Interventions using Digital Health Technology and Coaching Versus Usual Care among Men with Prostate Cancer II (Prostate 8 - II)Open
175518Gallium-68 PSMA-11 PET in patients with biochemical recurrenceOpen
17553A RANDOMIZED CLINICAL TRIAL TO EVALUATE A DECISION-SUPPORT TOOL FOR MEN WITH PROSTATE CANCEROpen
17556A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination DeficiencyOpen
17959A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid TumorsOpen
185511Immunogenic Priming with PSMA-Targeted Radioligand Therapy in Advanced Prostate Cancer: A Phase 1b Study of 177Lu-PSMA-617 in Combination with PembrolizumabOpen
185512VISION: An International, Prospective, Open-Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the treatment of Patients with Progressive PSMA-Positive Metastatic Castration Resistant Prostate Cancer (mCRPC)Open
185513Expanded Access Protocol: Gallium-68 PSMA-11 PET in prostate cancer patients Open
185517A Phase 3, Multi-Center, Open-Label Study to Assess the DiagNostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men with Suspected Recurrence of PrOstate CanceR (CONDOR)Open
18553A Phase 1/2 open-label, multi-center, safety and tolerability study of a single dose of 68 Ga-PSMA-R2 in patients with biochemical relapse (BR) and metastatic prostate cancer (mPCa)Open
18554Clinical Characteristics and Outcomes in Cancer Patients with CDK12 and Other DNA Damage Gene MutationsOpen
18555Expanded access use of ipatasertib in a patient with metastatic castration resistant prostate cancer with Akt mutationOpen
187014A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients with Advanced Prostate Cancer Refractory to Androgen TherapyOpen
18702An open-label multi-center phase II study of neoadjuvant atezolizumab-based combination therapy in men with localized prostate cancer prior to radical prostatectomy Open
18801Non-pharmacologic approaches to relieve pain and symptom distress among diverse hospitalized cancer patientsOpen
189517A Phase 1 Trial for Evaluation of Safety Pharmacokinetics, and 177Lu Radiation Dosimetry of CTT1403, a Peptidomimetic Inhibitor of Prostate Specific Membrane Antigen, in Metastatic Castration Resistant Prostate CancerOpen
18952A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor MalignanciesOpen
18954A PHASE 1 STUDY OF FOR46 ADMINISTERED EVERY 21 DAYS IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)Open
18958A Phase 1/2 open-label, multi-center, dose-escalation study of safety, tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of 177Lu-PSMA-R2 radio-ligand therapy in patients with prostate specific membrane antigen (PSMA) positive (68Ga-PSMA-R2) progressive metastatic castration-resistant prostate cancer, following previous systemic treatmentOpen
19551A Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination with the Anti-Programmed Cell Death 1 (PD-1) Monoclonal Antibody Pembrolizumab (PEMBRO; Keytruda) in Patients with Small Cell Neuroendocrine Prostate Cancer (SCNC; NEPC)Open
19553Mechanisms of Resistance to PSMA Radioligand Therapy: Radiation Resistance Versus DoseOpen
19952A Phase II basket study of the oral selective pan-FGFR inhibitor Debio 1347 in subjects with solid tumors harboring a fusion of FGFR1, FGFR2 or FGFR3 Open
19954A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176Open
AGCT1532Phase 3 Accelerated BEP Trial: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell TumoursOpen
APEC1621JNCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway MutationsOpen